Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations
Aurora
Aurora: Evaluation of an AI-Based Narrative Intervention for Emotional Well-Being, Identity Processes, and Recovery-Oriented Outcomes in Clinical and Non-Clinical Populations
1 other identifier
interventional
55
1 country
2
Brief Summary
Aurora is an interdisciplinary project evaluating a chatbot-mediated supportive care intervention designed to promote emotional expression, autobiographical meaning-making, identity processes, and emotional well-being through guided narrative reconstruction. The Aurora system provides a structured, person-centered storytelling process supported by generative AI and human facilitation. Under the supervision of a trained facilitator (licensed mental health professional), participants engage in guided reminiscence and storytelling sessions to co-create a personalized "life book." The chatbot is not a diagnostic or treatment tool; rather, it is intended to support emotional expression, narrative reconstruction, and recovery-oriented processes. The study includes three non-randomized arms implemented sequentially: (1) a single-session arm of healthy adults focused on acceptability, usability, and emotional safety; (2) a four-hour intervention arm of adults with DSM-5 diagnosed mental disorders in residential care; and (3) a four-hour intervention arm of healthy older adults aged 65 years and older. Quantitative outcomes assess affect, mental well-being, and recovery-related constructs. Additional measures include usability, satisfaction, and qualitative feedback. Ecological momentary assessment (EMA) is conducted in Arms 2 and 3.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2026
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 18, 2025
CompletedStudy Start
First participant enrolled
February 12, 2026
CompletedFirst Posted
Study publicly available on registry
March 27, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2026
CompletedMarch 27, 2026
March 1, 2026
2 months
December 18, 2025
March 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Positive Affect (I-PANAS-SF - Positive Affect subscale-pre-post session change)
Positive affect will be assessed using the Positive Affect (PA) subscale of the International Positive and Negative Affect Schedule - Short Form (I-PANAS-SF). Participants will rate their affect "right now." The endpoint is the change in PA from immediately before to immediately after each session across all treatment arms. Higher scores indicate higher positive affect.
Change from immediately before to immediately after each session, up to 2 weeks.
Negative Affect (I-PANAS-SF - Negative Affect subscale - pre-post session change)
Negative affect will be assessed using the Negative Affect (NA) subscale of the International Positive and Negative Affect Schedule - Short Form (I-PANAS-SF). Participants will rate their affect "right now." The endpoint is the change in NA from immediately before to immediately after each session across all treatment arms. Higher scores indicate higher negative affect.
Change from immediately before to immediately after each session, up to 2 weeks.
Secondary Outcomes (4)
Positive Affect (I-PANAS-SF - Positive Affect subscale - baseline to 1-week follow-up change)
Change from baseline at 1 week after end of intervention.
Negative Affect (I-PANAS-SF - baseline to 1-week follow-up change)
Change from baseline at 1 week after end of intervention.
Mental well-being (WEMWBS)
Change from baseline at 1 week after end of intervention.
Recovery-related outcomes aligned with CHIME framework
Change from baseline at 1 week after end of intervention.
Other Outcomes (3)
Usability (System Usability Scale, SUS)
Immediately after session (Arm 1); 1 week after end of intervention (Arms 2 and 3)
User experience and satisfaction
Immediately after session (Arm 1); 1 week after end of intervention (Arms 2 and 3)
Ecological Momentary Assessment (EMA)
Twice daily from 1 week before intervention to 1 week after end of intervention.
Study Arms (3)
Single-session - Healthy adults
EXPERIMENTALHealthy adults complete one Aurora session (single exposure) for platform refinement and usability assessment.
Four-hour program - Adults with DSM-5 diagnosed mental disorder in residential care
EXPERIMENTALAdults (aged ≥18 years) with a DSM-5 diagnosed mental disorder, residing in long-term mental health residential care facilities, complete a four-session guided narrative program over two weeks (two sessions per week, 1 hour per session) with facilitation by a licensed mental health professional.
Four-hour program - Healthy older adults (≥65 years)
EXPERIMENTALHealthy older adults (aged ≥65 years), with no self-reported diagnosis of a serious mental disorder, complete a two-session guided narrative program over two weeks (one session per week, 2 hours per session) with facilitation by a licensed mental health professional.
Interventions
Aurora is a guided narrative reconstruction chatbot combining structured storytelling and reminiscence with an AI-based conversational system and support from a trained facilitator. Participants co-create a personalized life narrative ("life book") with written content and optional audio contributions (with explicit consent). Sessions occur in a secure professional environment and are supervised by licensed mental health professionals to ensure emotional safety. Aurora is not a diagnostic tool and is intended to promote emotional expression, recovery-oriented processes, and emotional well-being. The intervention is delivered in structured guided sessions. Arm 1 receives a single-session version for refinement and usability assessment, whereas Arms 2 and 3 receive a 4-hour intervention delivered over two weeks. The total intervention dose is equivalent across Arms 2 and 3. Session structure differs to accommodate participant characteristics.
Eligibility Criteria
You may qualify if:
- Arm 1: Healthy Adults (Single-Session Intervention)
- Age 18 years or older at screening.
- Sufficient ability to read and understand Spanish to follow study instructions and complete questionnaires.
- Ability to engage in a brief guided interaction and complete self-report measures.
- Able and willing to provide written informed consent.
- \---
- Arm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care (4-hour Intervention)
- Age 18 years or older at screening.
- Currently residing in a participating long-term mental health residential care facility and expected to remain there for the duration of the intervention and post-assessment period.
- Documented diagnosis of a mental disorder according to DSM-5 criteria, confirmed by the treating clinician.
- Minimal clinical stability at baseline, defined as all of the following:
- Clinically stable in the judgment of the treating clinician.
- No requirement for acute psychiatric hospitalization or crisis intervention in the previous 4 weeks.
- Clinical Global Impression - Improvement (CGI-I) score between 3 and 5 inclusive during the 4 weeks prior to enrollment, indicating relative clinical stability.
- Sufficient ability to understand spoken and written Spanish to participate in study procedures.
- +11 more criteria
You may not qualify if:
- Arm 1: Healthy Adults
- Current acute medical or psychiatric condition that would compromise safe participation or data validity.
- Moderate or high acute suicide or self-harm risk at screening.
- Significant cognitive, communication, or comprehension impairment that would interfere with participation.
- Explicit refusal to participate.
- \---
- Arm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care
- Current acute psychiatric decompensation requiring crisis-level care.
- Moderate or high acute suicide or self-harm risk at screening or baseline.
- High risk of clinically significant emotional harm from autobiographical life review, defined as treating clinician judgment that narrative or reminiscence work is contraindicated due to one or more of the following:
- Severe clinical destabilization within the past 3 months.
- Trauma-related re-experiencing symptoms.
- Marked dissociative symptoms.
- Inability to provide informed consent, with no legal representative available when required, or lack of participant assent when applicable.
- Significant cognitive, communication, or comprehension impairment without available supports.
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universitat Autonoma de Barcelonalead
- Grup ATRAcollaborator
- AGAURcollaborator
- Institut Municipal de Persones amb Discapacitatcollaborator
- Parc Sanitari Sant Joan de Déucollaborator
- Universitat Oberta de Catalunyacollaborator
Study Sites (2)
Llar Residència Gràcia(Grup ATRA)
Barcelona, Barcelona, 08012, Spain
Department of Clinical and Health Psychology; Universitat Autònoma de Barcelona
Cerdanyola del Vallès, Barcelona, 08193, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Albert Feliu-Soler Associate Professor Serra Húnter Fellow, PhD
CONTACT
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor - Serra Húnter Fellow
Study Record Dates
First Submitted
December 18, 2025
First Posted
March 27, 2026
Study Start
February 12, 2026
Primary Completion
April 1, 2026
Study Completion
April 1, 2026
Last Updated
March 27, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to the sensitive nature of the data, which include mental health information and autobiographical narrative content from a vulnerable population. Data use is restricted to the approved study objectives under the conditions of the ethics committee approval and applicable data protection regulations (GDPR).